- Home
- DFLI vs BLRX Comparison
DFLI vs BLRX Comparison
Compare DFLI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFLI
- BLRX
- Stock Information
- Founded
- DFLI 2020
- BLRX 2003
- Country
- DFLI United States
- BLRX Israel
- Employees
- DFLI N/A
- BLRX N/A
- Industry
- DFLI Electronic Components
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- DFLI Technology
- BLRX Health Care
- Exchange
- DFLI Nasdaq
- BLRX Nasdaq
- Market Cap
- DFLI 14.5M
- BLRX 17.2M
- IPO Year
- DFLI N/A
- BLRX 2011
- Fundamental
- Price
- DFLI $0.29
- BLRX $3.87
- Analyst Decision
- DFLI Strong Buy
- BLRX Strong Buy
- Analyst Count
- DFLI 1
- BLRX 2
- Target Price
- DFLI $1.50
- BLRX $19.00
- AVG Volume (30 Days)
- DFLI 4.7M
- BLRX 31.9K
- Earning Date
- DFLI 11-13-2025
- BLRX 08-14-2025
- Dividend Yield
- DFLI N/A
- BLRX N/A
- EPS Growth
- DFLI N/A
- BLRX N/A
- EPS
- DFLI N/A
- BLRX N/A
- Revenue
- DFLI $54,536,000.00
- BLRX $17,251,000.00
- Revenue This Year
- DFLI $27.77
- BLRX N/A
- Revenue Next Year
- DFLI $42.02
- BLRX N/A
- P/E Ratio
- DFLI N/A
- BLRX N/A
- Revenue Growth
- DFLI 4.80
- BLRX 1.19
- 52 Week Low
- DFLI $0.15
- BLRX $2.30
- 52 Week High
- DFLI $5.78
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- DFLI 50.09
- BLRX 50.80
- Support Level
- DFLI $0.28
- BLRX $3.68
- Resistance Level
- DFLI $0.31
- BLRX $4.11
- Average True Range (ATR)
- DFLI 0.02
- BLRX 0.25
- MACD
- DFLI -0.00
- BLRX 0.03
- Stochastic Oscillator
- DFLI 59.04
- BLRX 48.07
About DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.